Trial Profile

Addition of Spironolactone in Patients With Resistant Arterial Hypertension

Status: Discontinued

Phase of Trial: Phase IV

Latest Information Update: 18 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Spironolactone (Primary)
Indications Resistant hypertension
Focus Therapeutic Use
Acronyms ASPIRANT; ASPIRANT-1

Most Recent Events

20 Jun 2012 Biomarkers information updated
19 Jun 2012 Additional lead trial centres identified as reported by ClinicalTrials.gov.
31 Aug 2011 Results of the substudy investigating microalbuminuria and proteinuria presented at the ESC Congress 2011: Annual Congress of the European Society of Cardiology.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com